Introduction:
Temozolomide, an alkylating agent, is a chemotherapeutic drug used
mainly in GBM (1). It was approved for use by the Food and Drug
Administration (FDA) in 2005 (2). Since then, it is being used globally
in patients with GBM to reduce disease progression. TMZ is used
initially with radiotherapy for six weeks (concurrent
chemo-radiotherapy-CRT) and subsequently alone as maintenance
chemotherapy. The first maintenance therapy cycle typically starts 28
days after chemo-radiotherapy (CRT). The first cycle dose is 150 mg/m2
and 200 mg/m2 for subsequent cycles (3). Like any
chemotherapy agent, TMZ is associated with multiple side effects, one of
which is hematological toxicity (1). Aplastic anemia is an emerging
adverse effect of TMZ (2,4-11). The crucial observation about AA
secondary to TMZ is its irreversible and dose-independent nature
(2,4-8). We have summarized the cases reported in the literature and
analyzed them for the patients’ age and sex, time of diagnosis of AA
after initiation of TMZ therapy and the nature of AA. We have also
reported a case of AA secondary to Temozolamide with characteristics in
keeping with most reported cases.